Stephen Threlkeld, MD
Infectious Disease · Memphis, TNNPI 1578530895
Payments from drug & device makers
What this record shows
This record is dominated by other: $16,800 of the $27,368 with a category attached, or 61.4%. Convatec Inc. accounts for 61.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $17,657 and has fallen 94.4% since, to $995 in 2025. Among infectious disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $46.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$17K
- Gilead$2K
- AbbVie$1K
- Merck$1K
- Insmed, Inc.$929
- Viiv Healthcare Company$863
- plus $5K from 27 others
What the payments were for
- Food & beverage$10,40738%
- Education$1611%
- Other$16,80061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 4 | $16,858 |
| Gilead | 95 | $1,580 |
| AbbVie(2 entities) | 114 | $1,438 |
| Merck | 63 | $1,006 |
| Insmed, Inc. | 42 | $929 |
| Viiv Healthcare Company | 65 | $863 |
| Astellas Pharma US Inc | 35 | $860 |
| Triad Life Sciences Inc. | 15 | $760 |
| Cipla USA Inc. | 1 | $495 |
| La Jolla Pharmaceutical Company | 21 | $370 |
| Pfizer | 20 | $340 |
| Tetraphase Pharmaceuticals, Inc. | 16 | $262 |
| Theratechnologies Inc. | 14 | $222 |
| Melinta Therapeutics, LLC | 11 | $154 |
| Johnson & Johnson | 11 | $143 |
| Abbott | 2 | $141 |
| Biotissue Holdings Inc. | 2 | $138 |
| Mayne Pharma Commercial LLC | 13 | $130 |
| Cumberland Pharmaceuticals, Inc. | 8 | $126 |
| Vyera Pharmaceuticals, LLC | 6 | $107 |
| Shionogi Inc | 4 | $81 |
| Organogenesis Inc. | 3 | $61 |
| Ferring Pharmaceuticals Inc. | 3 | $54 |
| EMD Serono, Inc. | 3 | $54 |
| Smith+Nephew | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 3 | $38 |
| CSL Behring | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Grifols USA, LLC | 1 | $15 |
| KCI USA, Inc. | 1 | $14 |
| Medela LLC | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$17,436
- ZEMDRI (PLAZOMICIN)$495
How this compares
$27,368 in reported general payments places this provider in the 90th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TeflaroCeftaroline Fosamil Acetate | 35 | $76,504 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $58,681 |
| Daptomycin | 60 | $13,083 |
| MicafunginMicafungin Sodium | 17 | $7,756 |
| Cefepime Hcl | 35 | $7,076 |
| ErtapenemErtapenem Sodium | 12 | $6,105 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 22 | $5,980 |
| Vancomycin Hcl | 25 | $3,172 |
| Rifampin | 20 | $1,537 |
| Cefdinir | 22 | $907 |
| Ethambutol Hcl | 14 | $422 |
| Azithromycin | 21 | $367 |
| Minocycline Hcl | 13 | $349 |
| Cephalexin | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieTeflaro | $1,438 | $76,50435 claims |
| GileadBiktarvy | $1,580 | $58,68113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 infectious disease providers in Tennessee.
Other infectious disease in Memphis
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Imad OmerMemphis$22K
- Margarita LamotheMemphis$12K
- Daniel MurrellMemphis$12K
- James DaleMemphis$8K
- Michael ThrelkeldMemphis$5K
- Kristie NowakMemphis$2K
- Shirin MazumderMemphis$2K
- Chiemeziem NwanyanwuMemphis$899
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.